Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Shares of Eli Lilly and Company (NYSE:LLY) dropped Thursday morning after the company announced that its diabetes treatment ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

Eli Lilly and Company (NYSE:LLY) is experiencing a strong analyst sentiment amid its expanding role in cutting-edge ...

Shares of Eli Lilly & Co. erased gains to trade down nearly 1% after White House press secretary Karoline Leavitt said the company was among 17 drugmakers that will be receiving letters from President ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might ...

Eli Lilly's first-quarter revenue grew 45% as combined sales for Mounjaro (diabetes) and Zepbound (obesity) rose dramatically to reach $6.2 billion, up year over year from $2.3 billion.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might ...